Table 2.
PPD by sP (mg/dL) Categories at Specified Study Quarters |
|||||
---|---|---|---|---|---|
Time Period | ≤5.5 | 5.6–6.5 | 6.6–7.5 | 7.6–8.5 | >8.5 |
Baseline (−Q1) | 7.3 (4.0) | 8.0 (3.9) | 8.8 (4.1) | 9.0 (3.7) | 9.8 (4.4) |
SO follow-up Q1 | 3.8 (1.7) | 4.0 (1.6) | 4.3 (1.8) | 4.4 (1.7) | 4.2 (1.6) |
SO follow-up Q2 | 3.9 (1.7) | 3.9 (1.5) | 4.7 (2.1) | 4.4 (2.0) | 4.3 (1.4) |
SO follow-up Q3 | 4.1 (1.8) | 4.4 (1.9) | 4.4 (1.8) | 4.3 (1.9) | 4.7 (2.2) |
SO follow-up Q4 | 4.0 (1.8) | 4.5 (1.8) | 4.6 (2.2) | 4.3 (2.0) | 4.8 (2.0) |
PPD, pills per day; SO, sucroferric oxyhydroxide; sP, serum phosphorus.
Summary estimates are presented as mean (standard deviation).